Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LABORATORY CORPORATION OF AMERICA HOLDINGS

(LH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/14/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
259.83(c) 260.43(c) 259.09(c) 260.18(c) 260.19(c) Last
620 467 519 793 552 083 518 115 885 324 Volume
+0.50% +0.23% -0.51% +0.42% 0.00% Change
More quotes
Financials (USD)
Sales 2021 14 550 M - -
Net income 2021 1 876 M - -
Net Debt 2021 3 668 M - -
P/E ratio 2021 13,5x
Yield 2021 -
Sales 2022 13 734 M - -
Net income 2022 1 218 M - -
Net Debt 2022 3 389 M - -
P/E ratio 2022 20,5x
Yield 2022 -
Capitalization 25 405 M 25 405 M -
EV / Sales 2021 2,00x
EV / Sales 2022 2,10x
Nbr of Employees 68 780
Free-Float 99,4%
More Financials
Company
Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The LCD segment is an independent clinical laboratory business, which... 
More about the company
Ratings of Laboratory Corporation of America Holdings
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about LABORATORY CORPORATION OF AMERICA HOLDINGS
06/14LABORATORY OF AMERICA  : OmniSeq Launch Genomic, Immune Profiling Test OmniSeq I..
MT
06/14LABORATORY OF AMERICA  : Labcorp And OmniSeq Launch INSIGHT℠, Next-Generat..
PR
06/09Labcorp Launches COVID-19 At-Home Test Kit at Walgreens
MT
06/08LABORATORY OF AMERICA  : Pixel by Labcorp® COVID-19 PCR Test Home Collection Kit..
BU
06/07CORRECTION : Mizuho Securities Maintains Laboratory Corp of America Holdings PT ..
MT
06/07LABORATORY OF AMERICA  : Mizuho Securities Adjusts Laboratory Corp of America Ho..
MT
06/03LABORATORY OF AMERICA  : Labcorp to Introduce Combined Oncology Offering at 2021..
AQ
06/02LABCORP  : to Introduce Combined Oncology Offering at 2021 ASCO® Annual Meeting
BU
05/26LABORATORY CORP OF AMERICA HOLDINGS  : Entry into a Material Definitive Agreemen..
AQ
05/24LABCORP  : Study Suggests COVID-19 Antibodies Remain at Least 10 Months After In..
BU
05/20LABORATORY OF AMERICA  : Argus Adjusts Price Target on Laboratory Corp. of Ameri..
MT
05/20LABORATORY OF AMERICA  : Labcorp Builds New Bioanalytical Lab in Singapore
MT
05/19LABCORP  : to Expand Bioanalytical Services With Integrated Laboratory in Singap..
BU
05/18LABORATORY OF AMERICA  : LABCORP TO SPEAK AT UBS GLOBAL HEALTHCARE VIRTUAL CONFE..
PU
05/18LABCORP  : to Speak at UBS Global Healthcare Virtual Conference
BU
More news
News in other languages on LABORATORY CORPORATION OF AMERICA HOLDINGS
06/07Warnungen vor Aufhebung der englischen Corona-Maßnahmen nehmen zu
2020ROCHE  : erhält FDA-Notfallzulassung für Sars-CoV-2-Antikörpertest
2020GENFIT  : signe un contrat exclusif de licence avec LabCorp pour un test de la N..
2019Schnellbahnstrecke zwischen Jerusalem und Tel Aviv eröffnet
2019STOCK MARKET PARIS : Les valeurs à suivre à Paris et en Europe (actualisé)
More news
Analyst Recommendations on LABORATORY CORPORATION OF AMERICA HOLDINGS
More recommendations
Stock Trading Strategies
LABORATORY CORPORATION OF AMERICA HOLDINGS - 02/01
Increase of volatility
BUY
More Stock Trading Analysis
Chart LABORATORY CORPORATION OF AMERICA HOLDINGS
Duration : Period :
Laboratory Corporation of America Holdings Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LABORATORY CORPORATION OF AMERICA HOLDINGS
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Average target price 298,31 $
Last Close Price 260,19 $
Spread / Highest target 30,3%
Spread / Average Target 14,6%
Spread / Lowest Target -5,07%
EPS Revisions
Managers and Directors
NameTitle
Adam H. Schechter Chairman, President & Chief Executive Officer
Glenn Andrew Eisenberg Chief Financial Officer & Executive Vice President
Lance V. Berberian Chief Information & Technology Officer & EVP
Brian J. Caveney Chief Medical Officer, EVP & President-Diagnostics
Stephen M. Anderson Chief Scientific Officer-Covance & Senior VP
Sector and Competitors